Rebecca Silbermann, MD
Hematology · Portland, ORNPI 1629187299
Payments from drug & device makers
Across 329 payments — averaging $13,315 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$2M
- Regeneron$779K
- Janssen Research & Development, LLC$656K
- Sanofi$253K
- E.r. Squibb & Sons, L.L.C.$248K
- Takeda Pharmaceuticals U.S.A., Inc.$224K
- plus $175K from 12 others
Across 24 payments — averaging $302.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$7K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 15 | $2,045,873 |
| Regeneron | 37 | $778,577 |
| Janssen Research & Development, LLC | 152 | $656,103 |
| Sanofi | 8 | $252,596 |
| E.r. Squibb & Sons, L.L.C. | 8 | $248,345 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $224,000 |
| GSK | 20 | $87,337 |
| Bristol Myers Squibb | 2 | $54,640 |
| Amgen | 1 | $13,072 |
| Pfizer | 6 | $6,726 |
| Johnson & Johnson | 8 | $4,936 |
| Janssen Scientific Affairs, LLC | 4 | $3,070 |
| Genentech USA, Inc. | 3 | $2,591 |
| Karyopharm Therapeutics Inc. | 1 | $1,500 |
| Adaptive Biotechnologies Corporation | 3 | $921 |
| Genentech, Inc. | 1 | $150 |
| Astrazeneca UK Limited | 1 | $96 |
| AstraZeneca | 1 | $55 |
How this compares
$4,380,590 in reported general payments places this provider in the 95th percentile of 27 hematology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Portland
- Eva MedvedovaPortland$4.4M
- John GodwinPortland$2.9M
- Jessica LeonardPortland$2.8M
- Emma ScottPortland$2.1M
- Craig OkadaPortland$1.7M
- Ronan SwordsPortland$1.2M
- Anusha VallurupalliPortland$1.2M
- Rachel CookPortland$1.1M
- Andy ChenPortland$407K
- Brandon Hayes LattinPortland$219K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.